Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 12—December 2020
CME ACTIVITY - Research

Tuberculosis among Children and Adolescents at HIV Treatment Centers in Sub-Saharan Africa

Anna M. Mandalakas1Comments to Author , Alexander W. Kay1, Jason M. Bacha, Tara Devezin, Rachel Golin, Katherine R. Simon, Dilsher Dhillon, Sandile Dlamini, Andrew DiNardo, Mogo Matshaba, Jill Sanders, Lineo Thahane, Pauline M. Amuge, Saeed Ahmed, Moorine P. Sekadde, Neway G. Fida, Bhekumusa Lukhele, Nodumo Chidah, David Damba, Joseph Mhango, Moses Chodota, Makhorong Matsoso, Angelina Kayabu, Richard S. Wanless, and Gordon E. Schutze
Author affiliations: Texas Children’s Hospital, Houston, Texas, USA (A.M. Manadalakas, A.W. Kay, J.M. Bacha, T. Devezin, K.R. Simon, D. Dhillon, S. Dlamini, A. DiNardo, M. Matshaba, J. Sanders, L. Thahane, S. Ahmed, N. Chidah, D. Damba, M. Chodota, M. Matsoso, A. Kayabu, R.S. Wanless, G.E. Schutze); Baylor College of Medicine, Houston (A.M. Manadalakas, A.W. Kay, J.M. Bacha, T. Devezin, D. Dhillon, A. DiNardo, B. Lukhele, R.S. Wanless, G.E. Schutze); Baylor College of Medicine Children’s Foundation Swaziland, Mbabane, Swaziland (A.W. Kay, S. Dlamini, B. Lukhele); Baylor College of Medicine Children's Foundation Tanzania, Mbeya, Tanzania (J.M. Bacha); US Agency for International Development, Washington, DC, USA (R. Golin); Baylor College of Medicine Children’s Foundation Malawi, Lilongwe, Malawi (K.R. Simon, S. Ahmed, J. Mhango); Technical Support to PEPFAR Programs in the Southern Africa Region, Lilongwe (K.R. Simon, S. Ahmed, J. Mhango); Botswana-Baylor Children’s Clinical Centre of Excellence, Gaborone, Botswana (M. Matshaba, N. Chidah); Baylor College of Medicine Children’s Foundation Lesotho, Maseru, Lesotho (J. Sanders, L. Thahane, M. Matsoso); Baylor College of Medicine Children’s Foundation Uganda, Kampala, Uganda (P.M. Amuge, D. Damba); National Tuberculosis and Leprosy Programme, Kampala, Uganda (M.P. Sekkade); US Agency for International Development, Pretoria, South Africa (N.G. Fida); Baylor College of Medicine Children’s Foundation Tanzania, Mwanza, Tanzania (M. Chodota, A. Kayabu)

Main Article

Table 4

Predictors of favorable TB outcomes against death in HIV-infected children and adolescents on ART at TB diagnosis, 2013–2017

Variable
 Odds ratio (95% CI)
 p value
Country
Swaziland, Lesotho, Malawi, Tanzania-Mbeya, Tanzania-Mwanza, and Uganda Referent
Botswana
 0.22 (0.01–1.90)
 0.0858
TB drug resistance
Not tested, multidrug resistance, not detected Referent
Mono INH resistance
 23.64 (0.00–28,630.46)
 0.3917
Immune status
Advanced Referent
Not advanced 0.59 (0.12–5.17) 0.2767
Severe
 4.29 (1.23–29.28)
 0.0294†
Each increasing WHO stage 2.18 (1.91–5.98) 0.001†

*Variables included were sex, COE, site of TB, TB treatment category, TB drug resistance, age at ATT initiation, days in care at COE, ART regimen pre-ATT initiation, immune status, ART TB days, total ART drugs pre-ATT treatment, ART category, and World Health Organization stage. ART, antiretroviral therapy; ATT, anti-TB therapy; COE, Center of Excellence; TB, tuberculosis.
†Significant result (p<0.05).

Main Article

1These authors contributed equally to this article.

Page created: September 10, 2020
Page updated: December 01, 2020
Page reviewed: December 01, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external